Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
2004 1
2005 3
2006 4
2008 5
2009 2
2010 9
2011 7
2012 9
2013 6
2014 1
2015 4
2016 1
2017 1
2018 4
2019 3
2020 3
Text availability
Article attribute
Article type
Publication date

Search Results

55 results
Results by year
Filters applied: . Clear all
Page 1
Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease.
Johnston TH, Lacoste AMB, Visanji NP, Lang AE, Fox SH, Brotchie JM. Johnston TH, et al. Neuropharmacology. 2019 Mar 15;147:11-27. doi: 10.1016/j.neuropharm.2018.05.035. Epub 2018 Jun 1. Neuropharmacology. 2019. PMID: 29907424 Review.
Pharmacokinetic/Pharmacodynamic Correlation Analysis of Amantadine for Levodopa-Induced Dyskinesia.
Brigham EF, Johnston TH, Brown C, Holt JDS, Fox SH, Hill MP, Howson PA, Brotchie JM, Nguyen JT. Brigham EF, et al. Among authors: johnston th. J Pharmacol Exp Ther. 2018 Nov;367(2):373-381. doi: 10.1124/jpet.118.247650. Epub 2018 Aug 7. J Pharmacol Exp Ther. 2018. PMID: 30087157
Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques.
Johnston TH, Geva M, Steiner L, Orbach A, Papapetropoulos S, Savola JM, Reynolds IJ, Ravenscroft P, Hill M, Fox SH, Brotchie JM, Laufer R, Hayden MR. Johnston TH, et al. Mov Disord. 2019 May;34(5):708-716. doi: 10.1002/mds.27565. Epub 2018 Dec 21. Mov Disord. 2019. PMID: 30575996
The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease.
Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM. Huot P, et al. Among authors: johnston th. Pharmacol Rev. 2013 Jan 10;65(1):171-222. doi: 10.1124/pr.111.005678. Print 2013 Jan. Pharmacol Rev. 2013. PMID: 23319549 Review.
A critique of available scales and presentation of the Non-Human Primate Dyskinesia Rating Scale.
Fox SH, Johnston TH, Li Q, Brotchie J, Bezard E. Fox SH, et al. Among authors: johnston th. Mov Disord. 2012 Sep 15;27(11):1373-8. doi: 10.1002/mds.25133. Epub 2012 Sep 13. Mov Disord. 2012. PMID: 22976821 Review.
Beneficial Effects of Trehalose on Striatal Dopaminergic Deficits in Rodent and Primate Models of Synucleinopathy in Parkinson's Disease.
Howson PA, Johnston TH, Ravenscroft P, Hill MP, Su J, Brotchie JM, Koprich JB. Howson PA, et al. Among authors: johnston th. J Pharmacol Exp Ther. 2019 Jun;369(3):364-374. doi: 10.1124/jpet.118.255695. Epub 2019 Mar 27. J Pharmacol Exp Ther. 2019. PMID: 30918068
Advances in the delivery of treatments for Parkinson's disease.
Johnston TH, Fox SH, Brotchie JM. Johnston TH, et al. Expert Opin Drug Deliv. 2005 Nov;2(6):1059-73. doi: 10.1517/17425247.2.6.1059. Expert Opin Drug Deliv. 2005. PMID: 16296809 Review.
Drugs in development for Parkinson's disease.
Johnston TH, Brotchie JM. Johnston TH, et al. Curr Opin Investig Drugs. 2004 Jul;5(7):720-6. Curr Opin Investig Drugs. 2004. PMID: 15298067 Review.
DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
Johnston TH, Versi E, Howson PA, Ravenscroft P, Fox SH, Hill MP, Reidenberg BE, Corey R, Brotchie JM. Johnston TH, et al. Neuropharmacology. 2018 Mar 15;131:116-127. doi: 10.1016/j.neuropharm.2017.11.046. Epub 2017 Nov 29. Neuropharmacology. 2018. PMID: 29197517
Drugs in development for Parkinson's disease: an update.
Johnston TH, Brotchie JM. Johnston TH, et al. Curr Opin Investig Drugs. 2006 Jan;7(1):25-32. Curr Opin Investig Drugs. 2006. PMID: 16425668 Review.
55 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback